Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DNA sequencing giant Illumina dropped a deal that would have brought it complementary technology. Going it alone might be a better bet for the company and investors.

Here’s Why Illumina Shares Barely Budged When It Gave Up On Its Takeover to The Tune Of $98 Million

Avid Bioservices

Endo International

IGM Biosciences Inc

IVERIC bio Inc

Kodiak Sciences Inc

Mylan

Neovasc

Pacira Pharmaceuticals

Pfizer

X4 Pharmaceuticals Inc

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfolio.

11 Biotechs and Pharma Stocks Being Given Huge Upside Targets for 2020

Thermo Fisher Scientific

Which of these two genetics stocks is more likely to continue rising in value?

Better Buy: Illumina vs. Thermo Fisher Scientific

ARK Genomic Revolution Multi-Sector ETF

Biotech firm Illumina, Inc. (NASDAQ: ILMN) scrapped a merger with Pacific Biosciences, but there’s still a lot to like about Illumina and for investors that can’t handle the stock’s over $300 price tag, the ARK Genomic Revolution Multi-Sector Fund (NYSEArca: ARKG) is an adequate proxy on the stock.

Illumina Stock Could Illuminate This Healthcare ETF

Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.

Illumina Stock Slips on Pacific Biosciences Deal Termination

Guardant Health Inc

Both stocks are risky, but for different reasons.

Better Buy:  Illumina vs.  Guardant Health

Pacific Biosciences of California

In its complaint last month, the FTC raised concerns that Illumina wanted the deal in order to prevent Pacific Biosciences from developing into a competitor in the market for next-generation DNA sequencing.

Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences

Illumina Inc. ILMN, -1.43% and Pacific Biosciences of California Inc. PACB, +0.39% on Thursday said they have agreed to drop plans to merge.

Illumina, Pacific Biosciences drop $1.2 billion merger agreement

The failed acquisition of Pacific Biosciences increases the pressure on a technology platform that may not be a perfect fit for personalized medicine.

What Happens Next for Illumina and Pacific Biosciences?

Osmotica Pharmaceuticals Plc

OSMT vs. ILMN: Which Stock Is the Better Value Option?

OSMT or ILMN: Which Is the Better Value Stock Right Now?

Shares of Pacific Biosciences of California Inc. PACB, -1.03% tumbled 3% in morning trading the day after the Federal Trade Commission announced plans to challenge Illumina Inc.

Pacific Biosciences stock falls on FTC challenge to Illumina deal

The Federal Trade Commission has filed a complaint aimed at stopping Illumina from purchasing Pacific Biosciences of California, the agency said on Tuesday.

FTC files complaint to block Illumina from buying PacBio

Alexion Pharma

ALXN vs. ILMN: Which Stock Is the Better Value Option?

Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.

Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits

Exact Sciences

Which stock wins in a one-on-one matchup between these two genomics revolution leaders?

Better Buy: Exact Sciences vs. Illumina

Emergent BioSolutions

EBS vs. ILMN: Which Stock Is the Better Value Option?

EBS or ILMN: Which Is the Better Value Stock Right Now?

You pay a high price for a company with near monopoly like Illumina. ILMN stock has 70% market share, but Its valuation is too high.

Investors Should Wait for Sky-High Valuations on Illumina Stock to Deflate

It's an inevitable step in the evolution of healthcare -- and one that could help Illumina grow into its premium valuation.

Illumina's Next Big Move: Distributed Diagnostics

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Invitae

REGENXBIO

Veracyte

As investors shift out of growth names and to more defensive pockets of the market, market watchers now see these biotech players as undervalued.

8 Undervalued Biotech Stocks to Watch Now

When market leaders in growth industries sell off, it opens opportunities for investors.

Illumina Selloff Is An Opportunity

Anheuser-Busch InBev

The last five trading days have been kind to stocks, but not every one enjoyed a lift in price.

2 Stocks That Flopped This Week

Which stock wins in a match-up between these two gene-sequencing leaders?

Better Buy:  Illumina vs. Thermo Fisher Scientific

Illumina stock crashed in above-average volume on Friday after the genetic testing company reiterated its growth outlook for 2019, implying slower-than-expected fourth-quarter sales.
The post Consumer DNA Testing Hits The Skids — And Takes Illumina Stock With It appeared first on Investor's Business Daily.

Consumer DNA Testing Hits The Skids — And Takes Illumina Stock With It

Illumina (ILMN) announces impressive Q3 results on the back of strong growth in the sequencing business.

Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View

The gene-sequencing pioneer beat Wall Street revenue and earnings estimates and raised its full-year earnings outlook. But it wasn't enough to make investors happy.

News for Illumina Stock (ILMN)